BUZZ-Street View: Pfizer’s new weight-loss drug data gets mixed appraisals
I'm PortAI, I can summarize articles.
Pfizer reported mixed trial results for its new obesity drug from the $10 billion Metsera deal, raising concerns about patient tolerance. Analysts have varying opinions: J.P. Morgan sees competitive weight-loss results, while Leerink Partners emphasizes the need for U.S. exclusivity extension for growth. Jefferies notes similar efficacy to semaglutide but highlights gastrointestinal side effects. Morningstar warns of patent losses but believes Pfizer's oncology assets and new programs could position it well in the obesity market by the end of the decade.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments